Medicare pilot program expands access to Wegovy, Zepbound for some seniors

A Medicare pilot program expands access to GLP-1 weight-loss medications like Wegovy and Zepbound for some seniors, offering subsidies as high as $50 per month. The program, running through 2027, requires a BMI above 35 or specific weight-related conditions for eligibility, though 6 million Medicare Part D recipients who might otherwise qualify will remain excluded. Concerns persist about potential bone and muscle density loss from rapid weight loss, but medical professionals suggest exercise can mitigate risks.